Physician profile
Ralph Crowe
NPI 1821282757
$13,151.89
in general payments reported to CMS, 2019-2025
48 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,243 · 2020: $1,312 · 2021: $2,589 · 2022: $1,736 · 2023: $2,064 · 2024: $2,391 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,272.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,827.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,218.36 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $1,018.10 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boston Scientific Corporation | $751.78 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $709.27 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $684.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $569.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $541.67 | 2022-2025 | Rexulti, Abilify Maintena |
| Shield Therapeutics INC | $497.03 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $436.49 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $435.70 | 2019-2022 | |
| Pfizer INC. | $396.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $383.22 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $375.66 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $359.43 | 2019-2024 | Xifaxan |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $341.68 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $219.19 | 2023-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.39 | 2024-2025 | Caplyta |
| Corcept Therapeutics | $186.62 | 2022-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $181.93 | 2019-2022 | |
| Amarin Pharma, INC. | $170.29 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.40 | 2019-2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $137.78 | 2019-2022 | |
| Lundbeck LLC | $134.94 | 2023-2025 | Rexulti, Vyepti |
| Esperion Therapeutics, INC. | $132.40 | 2021-2022 | |
| Exact Sciences Corporation | $124.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $118.88 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $105.65 | 2019-2023 | Verquvo, Vaxneuvance, Vaxelis |
| Nestle Healthcare Nutrition INC. | $79.08 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.34 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $59.00 | 2023-2024 | Quviviq |
| Dexcom, INC. | $48.25 | 2021-2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $45.28 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $41.63 | 2023-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company Ltd. | $38.90 | 2022 | |
| Hikma Pharmaceuticals USA | $38.33 | 2021 | |
| Eyevance Pharmaceuticals LLC | $38.33 | 2021 | |
| Scilex Pharmaceuticals INC. | $36.35 | 2022 | |
| Genentech USA, INC. | $35.39 | 2020 | |
| Abbott Laboratories | $34.62 | 2020-2024 | Freestyle Libre 3 |
| Allergan, INC. | $33.04 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $31.82 | 2024-2025 | Opsumit, Uptravi |
| Vanda Pharmaceuticals INC. | $25.27 | 2025 | Fanapt |
| Cranial Technologies, INC | $16.81 | 2024 | Doc Band |
| Tactile Systems Technology INC | $16.39 | 2022 | |
| Smith+Nephew, INC. | $13.36 | 2024 | Collagenase Santyl |
| Biohaven Pharmaceuticals, INC. | $11.70 | 2021 | |
| Eisai INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Crowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.